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Abstract
The blood-brain barrier prevents the entry of many therapeutic agents into the brain. Various nanocarriers have been
developed to help agents to cross this barrier, but they all have limitations, with regard to tissue-selectivity and their ability
to cross the endothelium. This study investigated the potential for 4 nm coated gold nanoparticles to act as selective
carriers across human brain endothelium and subsequently to enter astrocytes. The transfer rate of glucose-coated gold
nanoparticles across primary human brain endothelium was at least three times faster than across non-brain endothelia.
Movement of these nanoparticles occurred across the apical and basal plasma membranes via the cytosol with relatively
little vesicular or paracellular migration; antibiotics that interfere with vesicular transport did not block migration. The
transfer rate was also dependent on the surface coating of the nanoparticle and incubation temperature. Using a novel 3-
dimensional co-culture system, which includes primary human astrocytes and a brain endothelial cell line hCMEC/D3, we
demonstrated that the glucose-coated nanoparticles traverse the endothelium, move through the extracellular matrix and
localize in astrocytes. The movement of the nanoparticles through the matrix was .10 mm/hour and they appeared in the
nuclei of the astrocytes in considerable numbers. These nanoparticles have the correct properties for efficient and selective
carriers of therapeutic agents across the blood-brain barrier.
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Introduction
A major challenge for the pharmaceutical industry is the
delivery of therapeutic biomolecules and transgenes into the
central nervous system (CNS). The blood-brain barrier (BBB),
formed by microvascular endothelium, pericytes and astrocytes,
prevents the movement of most larger hydrophilic molecules
(.1 kDa) and many toxic agents. The key elements of the barrier
are continuous tight-junctions between endothelial cells, which
prevent molecules from diffusing into the brain by the paracellular
route, and ABC-transporters that actively pump xenobiotics out of
the brain [1,2]. In addition, brain endothelial cells have only low
levels of pinocytotic activity [3]. As a result, many drugs and larger
biomolecules, including cytokines and gene-modifying therapies,
which have considerable potential for the treatment of CNS
disease, are excluded by the endothelial barrier [4–7].
Considerable efforts have been made to find a way of
overcoming the blood-brain barrier, including the use of
nanoparticles as carriers [8]. Gold nanoparticles have the
advantage of easy production and chemical stability and they
have recently been tested in nanomedicine for both diagnosis and
therapy [9]. The gold core is inert but it does interact with
biological material and can have biological effects. To address this,
a variety of sizes and surface modifications have been investigated
which affect the specific behaviour of the nanoparticles [10–12].
However, there is comparatively little data on which nanoparticles
are selective for endothelium from different tissues.
Nanoparticle transport into a cell depends highly on the size
and surface coating of the nanoparticles. Relatively small gold
nanoparticles (,50 nm) may enter cells via an endocytic pathway
[13,14] and it has been calculated that a size of 27–30 nm is
optimal for endocytosis [15]. It has been thought that gold
nanoparticles do not enter the nucleus unless the cell is apoptotic
[16]. In contrast, they are often trapped in vesicles (endosomes)
[17–20] and can end up in lysosomes, with sensitive cargo being
digested by lysosomal enzymes, which presents an obstacle for
drug/gene delivery into tissues. Hence, in relation to the blood-
brain barrier, the ideal components of a CNS nanoparticle-based
drug delivery system are:
1. movement through the cellular cytosol, 2. selectivity for the
brain endothelium, 3. the ability to cross the brain endothelium
intact, 4. uptake by the target cell within the CNS and 5. low
toxicity and immunogenicity.
How can selectivity for the CNS be achieved? Since brain
endothelium has a number of specific receptors and transporters
which allow influx of nutrients into the brain, their ligands have
been exploited in attempts to develop CNS specific nanoparticles
[21]. For example, nanoparticles coated with ApoE (targeting the
LDL receptor) or OX26 antibody (targeting the transferrin
receptor) have both been used in CNS drug delivery [17,21]. An
alternative approach relies on the physical properties of the
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nanoparticles; it has been found that small gold nanoparticles can
directly penetrate the plasma membrane, and this property also
depends on the surface coating and structure of the nanoparticle
[22,23]. Moreover, the biophysical surface properties of brain
endothelium are different from non-brain endothelium with a high
negative surface charge, due to sulphated proteoglycans [24]. The
distinctive properties of brain endothelium imply that selective
targeting of nanoparticles to the CNS is possible.
In this study, we have chosen glucose-coated gold nanoparticles,
4 nm in size, with a 2 nm gold core [25]. These nanoparticles are
considerably smaller than nanoparticles used in related studies
[17]. Glucose-coated nanoparticles were initially selected because
the glucose transporter Glut-1 is expressed on brain endothelium
and astrocytes. However, the experimental data indicated that it is
the biophysical properties of these nanoparticles rather than
receptor-binding which is important for their transfer across brain
endothelium.
We tested whether these nanoparticles can be used as a
potential carrier across the blood-brain barrier, focusing on (1)
studying localization inside the cell; (2) comparison of uptake of
these nanoparticles by brain endothelium compared with endo-
thelia from other tissues (bone marrow and coronary artery) in
order to establish whether the glucose-coated nanoparticles are
CNS-selective; and (3) studying transfer across the brain endothe-
lium and into astrocytes using an in vitro 3D co-culture model.
We have also developed a novel model of the blood brain
barrier, in which human astrocytes are cultured in a 3-dimensional
(3D) collagen gel, beneath a monolayer of human brain
endothelium. This model is based on a 3D rat glial cell culture
system previously developed in our laboratories [26,27], which has
been modified to include primary human astrocytes and the brain
endothelial cell line hCMEC/D3 [28]. To investigate the
distribution of gold nanoparticles in cells, we have used
transmission electron microscopy (TEM) to give quantitative data
on the localization of the nanoparticles in different subcellular
compartments.
Materials and Methods
Ethical Statement
Anonymous tissue donations from elective surgical resections
were made according to a protocol approved by Oxfordshire
REC-C (07/H0606/97).
Endothelial, Astrocyte and Fibroblast Cultures
Primary human brain microvessel endothelium (1-BEC) was
obtained from surgical resection, undertaken to treat epilepsy, with
the informed, written consent of the patient. The cells were
isolated from a small area of unaffected tissue at the tip of the
temporal lobe, by collagenase/dispase digestion and isolation on
BSA and percoll gradients as previously described [29]. The cells
were cultured (passage-1) on collagen-coated flasks or tissue culture
inserts in EBM-2 MV medium (Lonza, Basel, Switzerland)
supplemented with 10% foetal bovine serum, hydrocortisone,
VEGF, epidermal growth factor (EGF), insulin-like growth factor I
(IGF-I), human fibroblast growth factor (FGF), ascorbic acid,
amphotericin-B and gentamicin sulphate according to the
manufacturer’s formulation. This same medium and conditions
were used for culturing human fibroblasts.
The human cerebral microvessel endothelial cell line hCMEC/
D3 [28] at passage 24–30 and primary human coronary artery
endothelial cells (CoAEC, Lonza; Cat. No. CC-2585) were
cultured in EBM-2 medium as described above but with 2.5%
foetal bovine serum. The human bone marrow endothelial cell line
BMEC [30] (kindly supplied by Dr Babette Weksler, Cornell,
University) was cultured in DMEM (Sigma-Aldrich) supplemented
with 10% foetal bovine serum with 100 U/ml penicillin and
100 mg/ml streptomycin (Invitrogen, UK). All the endothelial cells
were cultured at 37uC in a humidified atmosphere containing 5%
CO2, unless otherwise indicated.
Human foetal cortical astrocytes (used at passage 3–6), were
obtained from ScienCell Research Laboratories (Carlsbad, Ca).
The cells were maintained on collagen type-I coated tissue culture
dishes in human astrocyte medium (ScienCell, Carlsbad, Ca)
including 2% foetal bovine serum and recommended growth
supplements.
3D Collagen Gel Astrocyte Cultures and Astrocyte/
Endothelial Co-cultures
Collagen gels containing 1.26106 astrocytes per ml were
prepared in 24-well plates, with an initial volume of 450 ml
cellular collagen gel per well. Gels were composed of a 10% cell
suspension of human astrocytes (in DMEM), 10% 10x minimum
essential medium (MEM; Sigma-Aldrich) and 80% type I rat tail
collagen (2.5 mg/ml; First Link, Wolverhampton, UK([31]. The
collagen was diluted from a 5 mg/ml 0.6% acetic acid stock using
water, then mixed with MEM and neutralised using sodium
hydroxide (assessed by colour change of the phenol red indicator),
then the mixture was added to the cell suspension and mixed to
ensure even distribution of cells before transfer to the pre-warmed
24-well plate. Gelation took ,10 min at 37uC. The gels were
overlaid with astrocyte medium and incubated for 2 hrs before
being stabilised using RAFTTM absorbers (TAP Biosystems,
Royston, UK) for 15 min to remove fluid and reduce gels to
Table 1. The categories that were established to sort localization of glucose-coated gold nanoparticles in cells.
Category Description of nanoparticles (NPs) belonging to this category
Upper membrane NPs adhered to the apical surface of cell membrane
Lower membrane NPs adhered to the basal extracellular surface of the plasma membrane of a cell that was attached to the transwell insert; NPs
accumulated between the polyester membrane of the insert and the lower plasma membrane of the cells.
Cytosol NPs freely distributed in cytosol, usually not clumped
Vesicles NPs located in endosomes, lysosomes, granules, vacuoles or mitochondria*
Junction NPs in intercellular junctions
Nucleus NPs inside the nucleus
*even though nanoparticles were not definitely observed in mitochondria, we cannot exclude them from this category as during sectioning it is not always possible to
unambiguously identify every membrane surrounded organelle or granule.
doi:10.1371/journal.pone.0081043.t001
Nanoparticle Transfer across Brain Endothelium
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approximately 10% of their original volume. Astrocyte gels were
incubated for a further 24 hrs in astrocyte medium before being
overlaid with hCMEC/D3 cells at a density of 50,000 cells/cm2.
These co-cultures were incubated for 3 days in EBM2 medium
with 2.5% FBS before the nanoparticles were applied to the apical
surface in fresh media for 1, 3 or 8 hrs. After incubation with
nanoparticles, co-culture gels were washed63 in PBS and fixed in
2.5% glutaraldehyde in 0.1 M So¨rensons phosphate buffer for at
least 1 hour. They were further processed for transmission electron
microscopy (TEM) as described below for transwell inserts.
Gold Nanoparticle Transport Assay
Gold nanoparticles were synthesised by Midatech Ltd (Abing-
don, UK) as described previously [25] using a modification of the
Brust-Schiffrin method [32], replacing the 2-phase synthesis with a
single phase (water), as the ligands are water-soluble. The gold
core (diameter ,2 nm) was covalently coated with either b2-
mercaptoethoxy-glucose or glutathione, producing nanoparticles
coated with either glucose or glutathione, which increased the
hydrodynamic diameter of the particle to approximately 4 nm.
The nanoparticles have a structured surface with bands of ligand
as previously described for other nanoparticles of this class [22,33].
The particle size was checked by TEM and the chemical
characterisation was carried out by Malvern Instruments Ltd.
(Malvern, UK). The glucose-coated nanoparticles have a mean
molecular mass of 27 kDa.
For transfer assays, 12-well transwell inserts (Corning Costar)
were coated with collagen and seeded with 40,000 cells per well
and incubated for 2 or 3 days to reach confluence. The cells were
then washed in HBSS and gold nanoparticles were added to the
fresh culture medium (0.5 ml) in the upper chamber to a final
concentration of 8.16 mg/ml. The cultures were then incubated
for 0 hrs (10 min) to 22 hrs at 37uC. After the incubation with
nanoparticles, the inserts were washed 63 in PBS and fixed in
2.5% glutaraldehyde in 0.1 M So¨rensons phosphate buffer (PB) for
1 hour at room temperature. They were further processed for
TEM, as described below for inserts.
In experiments where inhibitor treatments were used, the
antibiotics were present for 1 hour before the experiment and
throughout the migration assay (3 hrs). The drugs selected were
cytochalasin-B, cytochalasin-D, nocodazole, nystatin and chlor-
promazine (Sigma-Aldrich). The concentrations were selected for
their ability to block vesicular transport in human brain
endothelial cells, and lack of cytotoxicity [34–37]. We also
confirmed that the cells were not affected by the agents at the
given concentrations for at least 8 hrs, as assessed by light and
electron microscopy.
Transmission Electron Microscopy (TEM)
Gold nanoparticles were visualized by silver enhancement
(Aurion, Netherlands) for 45 min at room temperature. Post-
fixation was carried out with 1% (w/v) osmium tetroxide in 0.1 M
PB for 1 hour and the transwell inserts were then washed in 0.1 M
PB for 10 min. The polyester membrane with the cultures were
excised from the insert and randomly cut into 2 segments of 3–
5 mm62 mm. These segments were progressively dehydrated in a
graded series of ethanol from 30% to 100%, embedded in Epon
resin and polymerised at 60uC for 48 hrs. Ultrathin sectioning was
performed using a Diatome diamond knife producing sections of
80–90 nm thickness, which were then collected on 261 mm
copper grids with pioloform film. The sections were counter-
stained at room temperature with 4% aqueous uranyl acetate for
35 min, washed three times, immersed in Reynolds lead citrate for
10 min and finally washed three times before air-drying. The
Figure 1. Electron micrographs of brain endothelial cells with
glucose-coated gold nanoparticles. (a) hCMEC/D3 cells and (b)
primary human brain endothelium 8 hours after application of glucose-
nanoparticles to the apical surface. Nanoparticles are located between
the basal plasma membrane and the transwell insert (arrows), for (b) the
lower area is also magnified in the top left corner 62. (c) A gold
nanoparticle in the intercellular junction of hCMEC/D3 cells (arrow) 3
hours after application of nanoparticles to the apical surface (detailed
magnification of the junction with nanoparticle is in the top left corner
67). The nanoparticles are also seen in the cytosol and vesicles. (d)
Detail of nanoparticles located in the cytosol and beneath the basal
membrane. (e) Detail of nanoparticles in a vesicle. Scale bars = 500 nm.
doi:10.1371/journal.pone.0081043.g001
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sections were observed on a transmission electron microscope
JEM-1400 operated at an accelerating voltage of 80 kV using a
magnification of65000 up to625,000.
To test if silver enhancement of cultures gives any background
labelling, we used cultures that did not contain any nanoparticles
(negative control) which were processed and treated as cultures
containing gold nanoparticles (above).
Sampling and Analysis of TEM Data
To choose representative data, a systematic sampling method
was used. Twenty-five images were taken from each section at
regular intervals, i.e. every fourth microscopic field containing a
cell. After this, every picture was analysed separately by counting
the observed nanoparticles which were assigned into six categories
(Table 1). The length of the cell membrane visible in each picture
(apical or basal membrane) was measured using software Image-J
version 1.43. Data points are based on a measurement of at least
50 cells from each experimental treatment or time-point (2
technical replicates with 25 images per replicate), (Fig. S1). Each
experiment was performed 2–4 times and the figures show data
from a representative experiment. The data are expressed either as
nanoparticles per micron of plasma membrane or nanoparticles
per cell. Note that the figures on the graphs refer to an 85 nm
thick section of the cell, and estimates of the total number of
nanoparticles per cell are made by a calculation based on the area
of the monolayers and the numbers of cells.
To evaluate astrocytes in 3-dimensional collagen gels, images
were taken of all astrocytes in each section; the area of each cell
and nucleus was measured (in microns squared) using Image-J and
the nanoparticles counted and assigned to the categories listed in
Table 1.
For astrocytes in co-culture with hCMEC/D3 cells in 3-D gels,
at least 240 astrocytes were evaluated in each gel, in order to
identify 50 cells containing nanoparticles in a gel (data collected
from 1 to 3 different ultrathin sections from each gel). The distance
of each astrocyte from the basal plasma membrane of the
Figure 2. The rate of transfer of glucose-coated gold nanoparticles across brain endothelium compared with non-brain
endothelium. (a) Brain endothelial hCMEC/D3 cells and human primary brain endothelium (1-BEC) were compared with a human bone marrow
endothelial cell line (BMEC) and human primary coronary artery endothelium (CoAEC). The values show the number of nanoparticles per cell, located
between the basal plasma membrane and the transwell insert 8 hrs after application to the apical surface. Values show mean 6SEM from at least 50
different cells, and two separate cultures. Note that the scale of the y-axis is expanded for the two non-brain endothelial cell types. (b) The bar chart
shows the number of nanoparticles per micron of the basal membrane after 8 hrs (mean 6SEM) from the four different cell types. Data was analysed
by Anova (P,0.05) followed by Tukey’s test to compare each pair of points. **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0081043.g002
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endothelium was also measured. All treatments were performed in
duplicate and the experiment was performed twice, with
representative data shown.
Viability Assay
An MTT assay was performed in a 96-well plate format to
assess cytotoxicity of the glucose-coated gold nanoparticles on
hCMEC/D3 cells. The cells were cultured for 2 days (seeding
density 20,000 cells per well) in EBM-2 medium. They were
washed and medium containing gold nanoparticles with different
concentrations (4, 8, 16 and 32 mg/ml) was added. All treatments
were performed in quadruplicate. The cells were incubated for
24 hrs. Negative controls were cells without nanoparticles; positive
controls were cells treated with digitonin (30 mg/ml for 30 min).
Wells containing medium only were used as a blank. After the
incubation, the medium was removed from all wells and medium
with 0.5 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; Sigma-Aldrich) was added to each well. The
plate was incubated for 3.5–4 hrs, the solution carefully aspirated
Figure 3. The effect of inhibitors of active cellular transport on
the localization of glucose-coated nanoparticles in hCMEC/D3
cells. (a) Cells were treated with 10 mg/ml nystatin, 5 mg/ml
cytochalasin-D, 5 mg/ml nocodazole, 10 mg/ml chlorpromazine, 5 mg/
ml cytochalasin-B. Data are expressed as the number of nanoparticles
located below the basal membrane compared with untreated cells.
Values are the mean 6 SEM of at least 50 cells. Anova indicates no
significant difference between treatments. (b) Localization of nanopar-
ticles in hCMEC/D3 cells at 8 hours after application following
incubation at 37uC or 30uC. U.M. = upper (apical) membrane, Cyt. = cy-
toplasmic, Ves. = vesicular, L.M. = lower (basal) membrane. The values
are the mean 6 SEM from at least 50 TEM images from a representative
experiment. Data was analysed by Anova; there was no significant
difference between the control and antibiotic treated samples
(P = 0.703).
doi:10.1371/journal.pone.0081043.g003
Figure 4. The rate of transport of different gold nanoparticles.
TEM of (a) 30 nm colloidal gold (Au30), (b) 4 nm glucose-coated
nanoparticles (Glu) and (c) 4 nm glutathione-coated nanoparticles (Gln).
(d) Rate of transport of the nanoparticles into and across hCMEC/D3
cells 22 hours after application. Values represent mean 6 SEM of the
number of nanoparticles located beneath the basal plasma membrane
or in the cytosol, based on at least 50 TEM images. Data were analysed
Nanoparticle Transfer across Brain Endothelium
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from the wells and 100 ml of DMSO (Sigma-Aldrich) was added to
each well. The plate was placed on an orbital shaker for 15 min
and absorbance was read at 540 nm on a plate reader.
Statistical Analysis
Comparison of different treatments was initially carried out by
one way Anova. If significant differences were found (p,0.05),
then the data was either analysed by Tukey’s test for pairwise
comparisons or Dunnett’s multiple comparison test to compare
different treatments with the control. The analysis was carried out
using Prism ‘Graphpad’ software.
Results
Cellular Localization of Glucose-coated Gold
Nanoparticles
To determine whether glucose-coated gold nanoparticles can
cross human brain endothelium, we applied the nanoparticles to
the apical surface of endothelial cell monolayers, incubated the
cultures for 0–22 hrs and detected them by transmission electron
microscopy (TEM). We used silver enhancement to increase the
size of nanoparticles to observable size (,20 nm). This works on a
principle of deposition of silver on the nanoparticle surface. We
confirmed that the silver enhancement itself does not cause
background labelling on cultures without nanoparticles (data not
shown).
The detected gold nanoparticles were counted and sorted into 6
different categories according to their localization: upper mem-
brane, lower membrane, cytosol, vesicles, junctions and nucleus
(Table 1). The initial experiments were carried out with primary
human brain endothelium (passage-1) or the brain endothelial cell
line hCMEC/D3 grown on transwell inserts. The results showed
that at time points 3 hrs and 8 hrs, large numbers of nanoparticles
were located below the basal plasma membrane (Fig. 1a, 1b).
These nanoparticles had accumulated in the extracellular matrix
between the basal plasma membrane and the transwell insert, as
they cannot enter the polyester membrane of the insert, except at
the pores. At 1–8 hrs the nanoparticles were also observed in the
cytosol but there were very few nanoparticles in vesicles, the
nucleus or in cellular junctions (Fig. 1c). Higher magnification
images confirmed that neither the cytosolic nanoparticles nor the
vesicular nanoparticles were enclosed in a phospholipid bilayer,
and that the nanoparticles at the basal membrane were
extracellular, confirming that they had crossed the cells
(Figs. 1d, 1e).
The presence of nanoparticles in the cytosol and their virtual
absence from cellular junctions suggested that they were directly
crossing the cells and were not reaching the basal plasma
membrane by the paracellular route. Nanoparticles were seen in
vesicles of hCMEC/D3 cells at 22 hrs (data not shown) but at this
time, they were in clumps and fewer were located beneath the
basal plasma membrane. Hence, in the early stages (3–8 hrs) the
nanoparticles appeared to cross the endothelium by non-vesicular
transport, but at the last time-point (22 hrs) they were mostly
aggregated (.50 nanoparticles per aggregate) and located in
vesicles.
Glucose-coated Gold Nanoparticles Preferentially Cross
Brain Endothelia
Next, we investigated the rate of transport in endothelia from
different tissues; we compared the two sources of brain endothe-
lium (primary brain and hCMEC/D3) with primary coronary
artery endothelium and a bone marrow endothelial cell line
BMEC (immortalised in a similar way to hCMEC/D3 cells). The
transport rate across the brain endothelial cell line hCMEC/D3
and the primary brain endothelium was approximately linear over
8 hours (Fig. 2a). Moreover, transport across both brain
endothelial cell lines was considerably more efficient than across
the two non-brain endothelial cells (Fig. 2b).
As an additional comparison, we used a non-endothelial cell
type, human fibroblasts, in which the rate of movement of the
nanoparticles was measured over 5 hrs with the same experimen-
tal setup as above. The rate of transfer to the lower membrane of
fibroblasts was ,3% of the rate of transfer across the primary
brain endothelium.
To estimate the total number of nanoparticles that were cell-
associated (inside the cell or at the bottom of the cell between the
basal plasma membrane and the membrane of the insert) we
counted nanoparticles in 1.5 mm (total length of the set of images)
6 85 nm (depth of the section) strips from 2 transwell inserts of
hCMEC/D3 cells (surface area = 2.55610210 m2).
We counted more than 18,000 nanoparticles in this area.
Therefore, the number of nanoparticles in the entire insert (surface
area = 1.1361024 m2 ) is 7.96109 nanoparticles.
Confluent monolayers of hCMEC/D3 cells on these transwell
inserts typically contain 105 cells, therefore the number of
nanoparticles per cell is 79,000 nanoparticles per cell.
It should be noted that this is a conservative estimate, since it
takes no account of failure to detect some of the nanoparticles by
TEM or nanoparticles that have moved down through the pores of
the filter.
Transport of Glucose-coated Gold Nanoparticles is by
Passive Uptake
To further investigate how the nanoparticles were traversing the
cell, experiments were carried out for 3 hours using hCMEC/D3
cells in the presence of agents that inhibit endocytosis and/or
vesicular transport, namely: chlorpromazine (clathrin-coated
vesicles), nocodazole (microtubules), cytochalasin-D (microfila-
by Anova (P,0.01 for the basal membrane data), followed by two-tailed
t-tests. *P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0081043.g004
Table 2. Accumulation of glucose-coated gold nanoparticles
in human primary astrocytes in co-cultures.
Timea Cellsb
% positive
cellsc Distanced Particles/celle
1 hour 411 7.462.0 10.661.6
[max 28]
3.5360.41
3 hours 308 15.961.0 16.762.6
[max 37]
4.1660.46
8 hours 240 19.560.6 15.561.4
[max 43]
3.7561.15
aTime after application of nanoparticles to the apical surface of the brain
endothelium (hCMEC/D3).
bTotal number of astrocytes observed.
cPercentage of astrocytes with intracellular nanoparticles, mean 6 SEM.
dThe distance of each astrocyte containing nanoparticles from the basal surface
of the endothelium in mm, mean 6SEM. Figures in brackets indicate the
maximum distance observed.
eNumber of nanoparticles observed in cells containing nanoparticles, mean
6SEM.
doi:10.1371/journal.pone.0081043.t002
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ments) and nystatin (caveolae and lipid rafts) [34–37]. If the
nanoparticles are transported by a particular vesicular system,
then the treatment should block transcytosis. The results showed
that at 3 hrs none of these treatments reduced the rate of
nanoparticle transfer (Fig. 3a). If vesicular transport is excluded,
one remaining mechanism for the transfer of nanoparticles across
the cells is by passive diffusion across the apical plasma membrane,
the cytosol and the basal membrane. Since the plasma membrane
limits free diffusion of hydrophilic molecules, we reasoned that
changing membrane fluidity (viscosity) would affect the rate of
transfer. (Membrane fluidity of mammalian cells is highly
temperature-dependent between 37uC and 30uC, while the rate
of diffusion is only marginally reduced). We found that reducing
the incubation temperature to 30uC reduced the number of
nanoparticles in the cytosol by 50% and the transfer rate to the
basal membrane by .80% (Fig. 3b).
Transfer Rate Depends on the Coating of the
Nanoparticle
We investigated the role of the ligand-coating on the rate of
transport. Initially, glucose-coated gold nanoparticles were selected
in this study because the glucose transporter, Glut-1 is expressed
on brain endothelium and astrocytes [38,39]. However, cytocha-
lasin-B which inhibits this transporter, had no effect on the rate of
transport of these nanoparticles (Fig. 3a).
We then compared glucose-coated nanoparticles with glutathi-
one-coated 4 nm nanoparticles to investigate further the impor-
tance of coating and 30 nm colloidal gold nanoparticles to
investigate the size dependence on the transport (Fig. 4).
Glucose-coated particles transferred more efficiently than gluta-
thione-coated nanoparticles and both 4 nm coated nanoparticles
were far more effective than the 30 nm colloidal gold nanopar-
ticles. This result indicates that the coating of the nanoparticle
affects the effectiveness of the transfer, even if the nanoparticle is
not using a cellular ligand-specific transport system.
Glucose-coated Gold Nanoparticles Travel through a 3D
Co-culture Model of the Blood-brain Barrier
The ultimate aim of the project was to determine whether the
nanoparticles could act as a carrier across the blood-brain barrier
and target glial cells. In the initial experiments we had noted that
the nanoparticles accumulated between the basal plasma mem-
brane of the endothelium and the transwell insert. Moreover, the
nanoparticles were also seen moving through the pores (400 nm in
diameter) of the polyester membrane of the transwell insert (the
nanoparticles cannot enter the membrane itself), which indicated
that they could be released by the endothelium and potentially
enter the interstitial spaces.
To assess the potential of the nanoparticles to target glial cells,
we used a novel co-culture system in which human astrocytes were
cultured in a 3-dimensional collagen gel, overlaid with a
monolayer of human brain endothelium (hCMEC/D3). Prelim-
inary experiments using TEM confirmed that the nanoparticles
could pass freely through the gel matrix and enter the astrocytes
(Fig. 5a). The nanoparticles were then applied to the endothelium
in co-culture and the rate of accumulation in astrocytes was
measured over 1–8 hrs. Observations were made from a sufficient
number of images, to include at least 50 astrocytes containing
nanoparticles (Fig. 5b). Over the 8 hr time course there was a
progressive increase in the percentage of astrocytes with detectable
nanoparticles (Table 2).
In order to check that the nanoparticles were not diffusing into
the collagen gel around the edge of the culture (i.e. where the 3D
collagen culture meets the wall of the transwell insert), we
compared the numbers of nanoparticles at the edge and middle of
the transwell inserts. If particles were diffusing from the edge we
would expect higher numbers at the edge of the transwell inserts.
In practice, the density of nanoparticles was higher in both
astrocytes and endothelium in the middle of the cultures, although
the difference was not statistically significant for either cell type
(Table 3).
Within the 3D collagen gel, astrocytes containing nanoparticles
are positioned at different depths from the endothelial monolayer
and it was possible to detect the spread of nanoparticles to deeper
astrocytes over 1–8 hrs, although the numbers of particles detected
per cell was similar at all times (Table 2). As the number of
Figure 5. Presence of glucose-coated gold nanoparticles in primary human astrocytes and/or brain endothelial cells hCMEC/D3 in
3D collagen gels. (a) Astrocyte culture 8 hours after application of glucose-coated gold nanoparticles to the gel surface. Nanoparticles are visible
both in the gel matrix and the astrocytes (arrows). (b) Co-culture of astrocytes and hCMEC/D3 cells 8 hours after application of glucose-coated gold
nanoparticles to the endothelial surface. Nanoparticles are detected both in the endothelium and the astrocyte (arrows). Small tears in the gel matrix
are sometimes produced during the sectioning due to the presence of silver-enhanced gold nanoparticles. Scale bars = 500 nm.
doi:10.1371/journal.pone.0081043.g005
Table 3. Location of glucose-coated gold nanoparticles in co-
cultures.
Cell type Edge of gela Middle of gela
P-value
(t-test)
Brain endothelium 57.1614.7 92.4623.5 0.25
Astrocytes 16.561.6 31.869.5 0.16
aNanoparticles per mm located in sections 85 nm deep at 8 hrs, in brain
endothelium or astrocytes (mean 6 SEM, n = 3 or 4). Data-points were obtained
by counting all nanoparticles in strips of 1–2 mm.
doi:10.1371/journal.pone.0081043.t003
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astrocytes with detectable nanoparticles reaches a plateau at 3–
8 hr, it suggests that the nanoparticles can pass through astrocytes
as well as endothelial cells, and hence they are not accumulating in
either cell type during this period. At 1 hour, the median distance
of the nanoparticles in astrocytes from the endothelium was
10.6 mm and the maximum distance was 28 mm, suggesting the
nanoparticles can permeate the gel moving on average at ,10 mm
per hour.
We then estimated the number of nanoparticles per astrocyte.
The sections produced for electron microscopy were 85 nm thick,
and all nanoparticles within the astrocytes in these sections were
counted. We observed on average 3.75 nanoparticles/cell at the 8
hour time point (Table 2). For a single astrocyte, up to 85 mm in
diameter, only 0.1% of the total nanoparticles are visible in the
85 nm section and we infer that each astrocyte could therefore
contain several hundred nanoparticles.
Cytotoxicity of Coated Gold Nanoparticles
To assess potential toxicity of the nanoparticles we performed
an MTT viability assay on hCMEC/D3 cells exposed to 4, 8, 16
or 32 mg/ml nanoparticles for 24 hrs (Fig. 6). There was no
reduction in the viability of the cells at any of the doses tested. In
one experiment, there was a significant increase in the absorbance
(optical density) of the cells treated with the highest dose of
glutathione-coated nanoparticles, which may be due to direct
absorbance by cell-associated gold nanoparticles. However, the
increase was not significant in 2 further repeats of the assay.
Discussion
Targeted delivery of drugs to cells of the CNS is a major
obstacle in the treatment of many diseases. Gold nanoparticles
have considerable potential as carriers of therapeutic agents across
the blood-brain barrier. This study shows that glucose-coated gold
nanoparticles are potential carriers for therapeutic agents into the
brain. We found that these nanoparticles are localized in the
cytosol rather than in endosomes, decreasing the risk for potential
degradation of the cargo. Moreover, they are preferentially taken
up by brain-endothelium compared to non-brain endothelia and
have low cytotoxicity.
Gold nanoparticles are not immunogenic and smaller nanopar-
ticles (3–5 nm) are not cytotoxic except at high doses [40–42]. The
glucose-coated gold nanoparticles used here caused no reduction
in viability of the endothelium following 24 hours treatment. The
study also demonstrated that the glucose-coated gold nanoparticles
can selectively cross human brain endothelium in vitro and localise
in astrocytes.
The 2D and 3D culture systems used in this study allowed
quantitation of the rate of transfer across brain endothelium and
analysis of the cellular mechanisms. The use of human cells is also
important since there are differences in the composition of the
blood-brain barrier between species. However, by comparison
with the situation in vivo, the barrier in vitro is less tight for ions and
smaller molecules [28]. As we were using static cultures, we
considered the possibility that sedimentation of the particles could
produce the results seen here. However, in the case of gold
nanoparticles less than 15 nm, sedimentation is negligible and
should not have an effect on the transport mechanism [43]. We
also considered the possibility that the nanoparticles could reach
the base of the endothelium by diffusion around the edge of the
culture wells. However, diffusion around the edge of the cultures
was excluded because there was no significant difference between
the numbers of nanoparticles at the centre and at the edge of the
cultures. Thus the culture systems appear to be suitable for
assessing trans-endothelial movement and subsequent localisation
of nanoparticles of this size (27 kDa).
Originally, we investigated glucose-coated nanoparticles due to
their possible binding to the glucose transporter Glut-1, present on
brain endothelium and astrocytes [38,39]. The finding that these
nanoparticles were selectively transported by brain endothelium,
by comparison with non-brain endothelium, initially supported the
view that the transfer was cell type specific and ligand-dependent.
However, the transfer was not blocked by antibiotics that interfere
with endocytosis or cytochalasin-B which blocks glucose uptake.
These results imply that transcytosis (which is normally low in
brain endothelium) and the glucose transporter are not responsible
for the transfer of the glucose-coated nanoparticles. Possibly, the
Figure 6. Viability of hCMEC/D3 cells treated with gold nanoparticles. Confluent monolayers of hCMEC/D3 cells were treated for 24 hr with
different levels of either glucose-coated or glutathione-coated gold nanoparticles and viability was assessed by MTT assay. Values are mean and SEM
of quadruplicate determinations (n = 4). The values were analysed by Anova (p,0.001) followed by Dunnet’s multiple comparison test, comparing
each nanoparticle treatment with the untreated cells (Con). Only one treatment was significantly different from the control (*P,0.001). Digitonin-
treated cells (Dig) were a positive control for cell death.
doi:10.1371/journal.pone.0081043.g006
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physical configuration of the glucose, in tightly-packed rings
around the 2 nm gold core, means that it cannot engage the Glut-
1 transporter effectively [44]. An alternative explanation for the
brain-selectivity is that transfer depends on other tissue-specific
properties of endothelial cells. In this respect, the surface
glycocalyx of brain endothelium is quite different from endothe-
lium in other tissues, with a very high negative charge [24]. Other
studies have implied that the surface charge of gold nanoparticles
affects their ability to penetrate the plasma membrane; cationic
nanoparticles are taken up more efficiently than anionic nano-
particles [23]. If the charge on the endothelial apical plasma
membrane is important in controlling the rate of transfer, then one
would predict that nanoparticles coated with glucose (uncharged)
would be transferred more effectively than those coated with
glutathione, which has a negative charge. This is indeed the case.
Other studies have shown that the type of coating can affect the
uptake of this class of nanoparticle, and critically determine
whether they enter endosomes or directly penetrate the plasma
membrane [22]. Since the nanoparticles were seen primarily in the
cytosol and in much smaller numbers in vesicles, the simplest
explanation is that the nanoparticles travel across the endothelium
itself mainly via the cytosol, which means that they must also cross
the apical and basal plasma membranes. Reducing the temper-
ature to 30uC reduced the number of particles in the cytosol by
50% and the rate of transfer across the cell by more than 80%.
This result is as expected for nanoparticles crossing the apical and
basal plasma membranes, assuming that membrane fluidity is an
important determinant of the transfer rate. The reduced rate of
transfer cannot be explained by a reduction in the diffusion
constant for the nanoparticles, which is only marginally reduced
between 37uC and 30uC. However, we cannot exclude the
possibility that some other cellular process, which is highly
temperature-dependent, could produce this reduction.
On transwell inserts, the nanoparticles accumulated in the
extracellular space between the basal plasma membrane and the
polyester membrane of the transwell insert. In the 3D co-cultures,
the nanoparticles are free to move away from the endothelium and
their distance from the endothelial monolayer increased over 1–
3 hrs (Table 2). They then appeared to accumulate in the
astrocytes, but this appearance may be because they move more
slowly through cells than the gel matrix. The localisation of
nanoparticles in co-cultures provided surprising data. It was
notable that nanoparticles were rarely seen in the nuclei of the
endothelium, but common in the nuclei of astrocytes, either in
single cell cultures or co-cultures. Previous work on gold
nanoparticles with a structured surface also showed that they
were completely excluded from the nucleus [22].
It is possible that changes in the surface coating of the
nanoparticles occur during the passage through the endothelium,
which means that they subsequently tend to localise to the
astrocyte nucleus. One possibility is that the reducing environment
of the endothelial cytosol causes release of some of the covalently-
bound glucose, resulting in a change in their charge and/or ability
to bind protein [33], which affects their ability to move through
different membranes, including the nuclear membrane. For
example, it has previously been shown that organic thiol ligands
can be released from the nanoparticle surface by exchange with
cellular glutathione [45]. However, any change in the properties of
the nanoparticle in the co-culture did not cause the nanoparticles
to aggregate; it is important that the nanoparticles are not trapped
in the endothelium if they are to be used to deliver a therapeutic
cargo to cells of the CNS.
The number of transferred nanoparticles is also an important
consideration. Our calculations suggest that .70,000 nanoparti-
cles crossed each endothelial cell and several hundred accumulat-
ed in each astrocyte. They therefore have the potential to carry an
effective dose of a toxic agent, a receptor agonist or a gene to the
target cells, if the process can be made to occur at a similar level
in vivo. Nanoparticles of this class are currently undergoing trials in
humans for the treatment of a number of diseases. It appears that
these smaller nanoparticles are less rapidly removed by the
mononuclear phagocyte system than larger ones [10]. Treatment
of CNS disease with nanoparticles has not yet been attempted in
humans, partly because of problems associated with getting them
to cross the blood-brain barrier. Studies in animals have shown
that gold nanoparticles can be used for drug-delivery or for
imaging in the CNS or for enhancing radiotherapy of brain
tumours [8,9,46]. Our study shows that 4 nm glucose-coated gold
nanoparticles are able to move across the cell through its cytosol,
are selective for human brain endothelium and are able to enter
the astrocytes. We imply that they have potential as a delivery
system for therapeutic agents to cells within the CNS, and we are
currently developing the nanoparticles as a gene-delivery system.
We are also first to examine the transport system of nanoparticles
in co-culture of two different cell types at the same time in vitro.
Supporting Information
Figure S1 The experimental setup for gold-nanoparticle
experiments with transwell inserts. Each experimental
treatment (or control) has been performed in duplicates in a
single experiment and three independent experiments were
performed.
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